Document is current
Any future updates will be listed below
-
Authors
Váradi, Melinda
Horváth, Orsolya
Módos, Orsolya
Fazekas, Tamás
Grunewald, Camilla M.
Niegisch, Günter
Krafft, Ulrich
Grünwald, Viktor
Hadaschik, Boris
Olah, Csilla
Maráz, Anikó
Furka, Andrea
Szűcs, Miklós
Nyirády, Péter
Szarvas, Tibor
-
Funding
Funding for this research was provided by:
New National Excellence Program of the Ministry for Innovation and Technology (ÚNKP-22-3-1-SE-19, ÚNKP-21-5-SE-3)
János Bolyai Research Scholarship of the Hungarian Academy of Sciences (BO/00451/20/5)
Ministry for Innovation and Technology (K139059)
Semmelweis University
- License Information
-
More Information
Article History
Received: 10 May 2023
Accepted: 3 October 2023
First Online: 13 October 2023
Competing interests
: Boris Hadaschik has had advisory roles for ABX, AAA/Novartis, Astellas, Astra-Zeneca, Bayer, Bristol Myers Squibb, Janssen R&D, Lightpoint Medical, Inc., and Pfizer; has received research funding from Astellas, Bristol Myers Squibb, AAA/Novartis, German Research Foundation, Janssen R&D, and Pfizer; and has received compensation for travel from Astellas, AstraZeneca, Bayer, and Janssen R&D. Günter Niegisch reports honoraria for lectures, symposia from Roche Pharma, MEDAC, Pfizer, BMS, AstraZeneca; and has had advisory roles for Roche Pharma, Sanofi, BMS, Merck Serono, Pfizer, MEDAC, Ipsen, Janssen; and reports support for travel expenses, congress fees from Roche Pharma, Pfizer, Merck, AstraZeneca. Viktor Grünwald has had advisory roles for Bristol-Myers Squibb, Pfizer, MSD Oncology, Merck HealthCare, Ipsen, Eisai, Debiopharm, PCI Biotech, Cureteq, Oncorena and has received compensation for travel from Pfizer, Ipsen, Merck HealthCare, and reports honoraria from Bristol-Myers Squibb, Pfizer, Ipsen, Eisai, MSD Oncology, Merck HealthCare, EUSAPharm, Apogepha, Ono Pharmaceutical. Ulrich Krafft has received research funding from Bristol Myers Sqibb, Novartis / AAA, and has received compensation for travel from Janssen Research funding, Bristol Myers Sqibb, Novartis/AAA. Camilla M. Grunewald has had advisory roles for Ferring. The remaining authors have no conflicts of interest to declare.
